Lapatinib (Tykerb, Tyverb), a dual EGFR-HER2 inhibitor [121], was tested in a multicenter phase I trial in combination with carboplatin in patients with platinum-sensitive recurrent ovarian cancer [122]. Here, ERBB2 is linked to ovarian cancer.